- Home
- ASRT vs ESLA Comparison
ASRT vs ESLA Comparison
Compare ASRT & ESLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASRT | ESLA |
|---|---|---|
| Founded | 1995 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.0M | 60.9M |
| IPO Year | 2004 | N/A |
Fundamental Metrics
Financial Performance| Metric | ASRT | ESLA |
|---|---|---|
| Price | $11.94 | $1.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $35.00 | $8.00 |
| AVG Volume (30 Days) | 33.6K | ★ 391.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 95.07 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $124,961,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.42 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.51 | $0.73 |
| 52 Week High | $12.95 | $3.15 |
Technical Indicators
Market Signals| Indicator | ASRT | ESLA |
|---|---|---|
| Relative Strength Index (RSI) | 57.80 | 43.59 |
| Support Level | $0.67 | $0.86 |
| Resistance Level | $12.75 | $1.18 |
| Average True Range (ATR) | 0.50 | 0.13 |
| MACD | -0.23 | -0.00 |
| Stochastic Oscillator | 45.66 | 32.05 |
Price Performance
Historical ComparisonAbout ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.
About ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.